Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 1, 2008, Pages 148-154

  Guerin, Maryse ^a,b,d   Le Goff, Wilfried ^a,b   Duchene, Emilie ^a,b   Julia, Zélie ^a,b   Nguyen, Tu ^c   Thuren, Tom ^c   Shear, Charles L ^c   Chapman, M John ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CETP; High density lipoprotein; Postprandial hypertriglyceridemia; Torcetrapib

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; ATHEROGENESIS; CHOLESTEROL DIET; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERLIPIDEMIA; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHYLOMICRONS; DIETARY FATS; DIETARY PROTEINS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRROLES; QUINOLINES;

EID: 37549056925     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.151688     Document Type: Article

References (32)

1. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1995;6:123-129.
2. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997;38:2173-2192.
3. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 1995;41:153-158.
4. Castro GR, Fielding CJ. Effects of postprandial lipemia on plasma cholesterol metabolism. J Clin Invest. 1985;75:874-882.
5. Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis. 1998;141:87-98.
6. Tall A, Sammett D, Granot E. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia. J Clin Invest. 1986;77:1163-1172.
7. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004;101:17-38.
8. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 1990;31:567-582.
9. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis. 2002;164:129-145.
10. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res. 2002;43:1652-1660.
11. Guerin M, Egger P, Le Goff W, Soudant C, Dupuis R, Chapman MJ. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab. 2002;87:4991-5000.
12. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
13. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2106-2112.
14. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036.
15. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537-552.
16. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-497.
17. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
18. Millar JS, Brousseau ME, Diffenderfer MR, Barret PHR, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, and Rader DJ. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arteriosclerol Thromb VascBiol. 2006;26:1350-1356.
19. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27:257-260.
20. Inazu A, Nakajima K, Nakano T, Niimi M, Kawashiri MA, Nohara A, Kobayashi J, Mabuchi H. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis. 2007;29:29.
21. Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: Relationship between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res. 1995;36:158-171.
22. Björkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, Shepherd J, Stewart P, and Karpe F. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res. 1996;37:76-86.
23. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci U S A. 1983;80:1449-1453.
24. Couillard C, Bergeron N, Bergeron J, Pascot A, Mauriege P, Tremblay A, Prud'homme D, Bouchard C, Despres JP. Metabolic heterogeneity underlying postprandial lipemia among men with low fasting high density lipoprotein cholesterol concentrations. J Clin Endocrinol Metab. 2000;85:4575-4582.
25. Castro GR, Fielding CJ. Evidence for the distribution of apolipoprotein E between lipoprotein classes in human normocholesterolemic plasma and for the origin of unassociated apolipoprotein E (Lp-E). J Lipid Res. 1984;25:58-67.
26. Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G. A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A. 1994;91:1834-1838.
27. Krimbou L, Tremblay M, Davignon J, Cohn JS. Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE. J Lipid Res. 1997;38:35-48.
28. Krimbou L, Marcil M, Chiba H, Genest J Jr. Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles. J Lipid Res. 2003;44:884-892.
29. Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res. 2004;45:448-455.
30. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR. Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132-1138.
31. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
32. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.